CTOs on the Move

Massachusetts Medical Society

www.massmed.org

 
The Massachusetts Medical Society is the oldest, most distinguished and prestigious continuously operating state medical association in the United States and the world.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.massmed.org
  • 860, Winter Street
    Waltham, MA USA 02451
  • Phone: 800.322.2303

Executives

Name Title Contact Details
Jacqui Boire
Director, Technology Strategy and Planning Profile

Similar Companies

Diamatrix

Founded in 1993, Diamatrix helped usher in a new era of cataract surgery with its revolutionary Trapezoid diamond blade. Designed in conjunction with Clear Cornea pioneer, Dr. Charles H. Williamson, M.D. of the Williamson Eye Center in Baton Rouge, thi...

BioVest International

BioVest International is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MAP Pharmaceuticals

MAP Pharmaceuticals is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CNS Healthcare

Providing mental health and substance use disorder services for children, youth, and adults. No insurance needed. #EndStigma

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.